ASX:TLXBiotechs
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Reaffirmed 2026 Guidance And Pipeline Progress
Telix Pharmaceuticals (ASX:TLX) has caught investor attention after reaffirming its 2026 revenue guidance of US$950 million to US$970 million and reporting progress across key late stage radiopharmaceutical programs.
See our latest analysis for Telix Pharmaceuticals.
The reaffirmed 2026 revenue guidance and recent clinical and regulatory milestones appear to have supported a 26.33% 1 month share price return to A$13.58. However, the 1 year total shareholder return of a 45.26% loss contrasts...